Alkeus Pharmaceuticals Presents Positive Gildeuretinol Trial Results at American Academy of Ophthalmology, Demonstrating Significant Slowing of Retinal Atrophic Lesions in Stargardt Disease

Primary endpoint met, demonstrating a 21% slowing (p<0.001) in the growth rate of atrophic retinal lesions compared to the untreated arm; 28% reduction (p<0.001) using observed atrophic area. Patients receiving gildeuretinol showed 80% slower loss of retinal sensitivity compared to [...]

By |2024-02-13T14:13:56+00:00November 3rd, 2023|

EYLEA HD Injection Approved by FDA for Treatment of Wet Age-Related Macular Degeneration (WAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)

August 18, 2023 at 6:35 PM EDT Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer injections First and only treatment [...]

By |2024-02-13T14:14:59+00:00September 5th, 2023|

SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA)

WALTHAM, Mass., July 30, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from the GALE extension study following 30 months of continuous treatment with SYFOVRE® (pegcetacoplan injection), the first and only FDA approved treatment for geographic atrophy [...]

By |2024-02-13T14:17:22+00:00July 31st, 2023|

New Treatment for AMD Accepted for FDA Priority Review

February 23, 2023 at 7:00 AM EST AFLIBERCEPT 8 MG BLA FOR TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION AND DIABETIC MACULAR EDEMA ACCEPTED FOR FDA PRIORITY REVIEW BLA supported by two pivotal trials demonstrating non-inferior vision gains to EYLEA® (aflibercept) Injection, [...]

By |2024-02-13T14:18:37+00:00March 7th, 2023|

Next Stop: AMD Central

Dawn Prall and Joshua Dunaief discuss AMD Central, a new site for people living with the condition Recently, I talked to Dawn Prall, founder and executive director of The SupportSight Foundation, and Joshua L. Dunaief, Adele Niessen Professor of Ophthalmology [...]

By |2021-09-17T17:50:12+00:00September 17th, 2021|
Go to Top